艾德生物
(300685)
| 流通市值：89.30亿 | | | 总市值：89.74亿 |
| 流通股本：3.90亿 | | | 总股本：3.92亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 579,344,557.65 | 272,090,793.91 | 1,108,948,700.11 | 847,967,831.38 |
| 营业收入 | 579,344,557.65 | 272,090,793.91 | 1,108,948,700.11 | 847,967,831.38 |
| 二、营业总成本 | 358,787,743.26 | 171,878,070.83 | 793,982,033.11 | 596,597,050.32 |
| 营业成本 | 92,683,800.76 | 44,947,949.58 | 169,145,096.25 | 129,440,425.59 |
| 税金及附加 | 6,980,665.37 | 3,276,001.9 | 5,003,157.54 | 3,704,087.49 |
| 销售费用 | 149,133,204.14 | 71,810,221.37 | 358,816,272.74 | 252,002,610.11 |
| 管理费用 | 43,671,009.11 | 20,682,579.95 | 72,214,299.19 | 58,257,058.21 |
| 研发费用 | 90,526,230.52 | 41,536,126.88 | 216,114,223.25 | 164,361,893.33 |
| 财务费用 | -24,207,166.65 | -10,374,808.85 | -27,311,015.86 | -11,169,024.4 |
| 其中:利息费用 | 1,052,853.8 | 336,303.08 | 1,339,204.65 | 906,160.56 |
| 其中:利息收入 | 15,873,970.86 | 7,353,176.83 | 26,579,322.2 | 19,560,759.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,241,563.21 | 1,814,123.84 | 8,768,533.37 | 6,409,871.62 |
| 加:投资收益 | 249,174.3 | -706,707.39 | -9,254,440.03 | -229,685.66 |
| 资产处置收益 | -44,133.07 | -151,135.17 | -1,063,253.41 | 15,576.72 |
| 资产减值损失(新) | 55,922.24 | 66,217.25 | -8,150,640.86 | -7,967,978.99 |
| 信用减值损失(新) | -5,726,317.57 | -1,600,193.06 | -30,218,314.54 | -7,794,373.01 |
| 其他收益 | 4,405,158.18 | 2,447,782.86 | 17,929,432.91 | 11,399,317.93 |
| 四、营业利润 | 222,738,181.68 | 102,082,811.41 | 292,977,984.44 | 253,203,509.67 |
| 加:营业外收入 | 203,350.51 | 5,000.92 | 176,975.13 | 45,576.79 |
| 减:营业外支出 | 3,431,680.77 | 294,312.21 | 3,274,297.22 | 2,142,440.55 |
| 五、利润总额 | 219,509,851.42 | 101,793,500.12 | 289,880,662.35 | 251,106,645.91 |
| 减:所得税费用 | 30,472,468.46 | 11,321,721.6 | 35,017,217.4 | 23,836,108.42 |
| 六、净利润 | 189,037,382.96 | 90,471,778.52 | 254,863,444.95 | 227,270,537.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 189,037,382.96 | 90,471,778.52 | 254,863,444.95 | 227,270,537.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 189,037,382.96 | 90,471,778.52 | 254,863,444.95 | 227,270,537.49 |
| 扣除非经常损益后的净利润 | 184,796,186.31 | 87,223,537.32 | 233,087,950.27 | 212,122,662.57 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.48 | 0.23 | 0.64 | 0.57 |
| (二)稀释每股收益 | 0.48 | 0.23 | 0.64 | 0.57 |
| 八、其他综合收益 | 56,175.38 | - | -204,431.24 | 56,809.94 |
| 归属于母公司股东的其他综合收益 | 56,175.38 | - | -204,431.24 | 56,809.94 |
| 九、综合收益总额 | 189,093,558.34 | 90,471,778.52 | 254,659,013.71 | 227,327,347.43 |
| 归属于母公司股东的综合收益总额 | 189,093,558.34 | 90,471,778.52 | 254,659,013.71 | 227,327,347.43 |
| 公告日期 | 2025-07-29 | 2025-04-22 | 2025-04-22 | 2024-10-22 |
| 审计意见(境内) | | | 标准无保留意见 | |